Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism, chronic anovulation, polycystic ovaries at ultrasound evaluation, and quite frequently by insulin resistance or compensatory hyperinsulinemia. Attention has been given to the role of inositol-phosphoglycan (IPG) mediators of insulin action and growing evidences suggest that a deficiency of D-chiro-inositol (DCI) containing IPG might be at the basis of insulin resistance, frequent in PCOS patients. On such basis, we investigated the efficacy on insulin sensitivity and hormonal parameters of 8 weeks treatment with myo-inositol (MYO) (Inofert, ItalPharmaco, Milano, Italy) at the dosage of 2 g day in a group (n = 42) of obese PCOS patients,. After the treatment interval body mass index (BMI) and insulin resistance decreased together with luteinizing hormone (LH), LH/FSH and insulin. When subdividing the patients according to their fasting insulin levels, Group A (n = 15) insulin below 12 µU/ml and Group B (n = 27) insulin above 12 µU/ml, MYO treatment induced similar changes in both groups but only patients of Group B showed the significant decrease of both fasting insulin plasma levels (from 20.3 ± 1.8 to 12.9 ± 1.8 µU/ml, p < 0.00001) and of area under the curve (AUC) of insulin under oral glucose tolerance test (OGTT). In conclusion, our study supports the hypothesis that MYO administration is more effective in obese patients with high fasting insulin plasma levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Papaleo, E., Unfer, V., Baillargeon, J.-P., Fusi, F., Occhi, F., & De Santis, L. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.01.088 · Cited by 197 · cited 1×
“Recently more clinical emphasis has been given to the use of inositol, both as myo-inositol (MYO [4,17,18]) or DCI [19], keeping in mind that a precise relationship exists between these two.”
BackgroundRetractedProfound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Ovulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary Syndrome
Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., & Allan, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401703 · Cited by 518 · cited 2×
“and non-obese women [7], the use of insulin sensitizers has been proposed to both obese and lean women with PCOS [8,11,12] to increase the frequency of ovulation and to improve the endocrine milieu [8,13].”
Genazzani, A. D., Lanzoni, C., Ricchieri, F., & Jasonni, V. M. (2008) · Gynecological Endocrinology · doi:10.1080/09513590801893232 · Cited by 221 · cited 5×
“Indeed, MYO administration significantly improved insulin sensitivity as demonstrated by the significant reduction of both insulin plasma levels and of the AUC of insulin, similarly to our previous reports [4].”
BackgroundResultSelf-citationSun, T.-H., Heimark, D. B., Nguygen, T., Nadler, J. L., & Larner, J. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00313-3 · Cited by 144 · cited 1×
“In fact DCI is synthesized by an epimerase that converts MYO into DCI and, depending on the specific needs of the two molecules, each tissue has a typical conversion rate [20,21].”
BackgroundUse of metformin in the treatment of polycystic ovary syndrome
Genazzani, A. D., Ricchieri, F., & Lanzoni, C. (2010) · Women's Health · doi:10.2217/whe.10.43 · Cited by 51
Self-citationd-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review
Galazis, N., Galazi, M., & Atiomo, W. (2011) · Gynecological Endocrinology · doi:10.3109/09513590.2010.538099 · Cited by 46 · cited 1×
“Recently more clinical emphasis has been given to the use of inositol, both as myo-inositol (MYO [4,17,18]) or DCI [19], keeping in mind that a precise relationship exists between these two.”
Background
Cited by
Poly Cystic Ovarian Syndrome: An Updated Overview
El Hayek, S., Bitar, L., Hamdar, L. H., Mirza, F. G., & Daoud, G. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00124 · Cited by 323
Kamenov, Z., & Gateva, A. (2020) · Molecules · doi:10.3390/molecules25235566 · Cited by 100
“[91] showed a nonsignificant change of BMI, although improvement of other PCOS-related parameters was improved.”
ResultInositol and human reproduction. From cellular metabolism to clinical use
Milewska, E. M., Czyzyk, A., Meczekalski, B., & Genazzani, A. D. (2016) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1188282 · Cited by 69
“Further, inositol treatment has had a positive impact on ovulation and cycle regularity [37,46,47].”
BackgroundSelf-citationShokrpour, M., Foroozanfard, F., Afshar Ebrahimi, F., Vahedpoor, Z., Aghadavod, E., Ghaderi, A., & Asemi, Z. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1540570 · Cited by 63
Tagliaferri, V., Romualdi, D., Immediata, V., De Cicco, S., Di Florio, C., Lanzone, A., & Guido, M. (2017) · Clinical Endocrinology · doi:10.1111/cen.13304 · Cited by 40
Metadata
- Authors
- Genazzani, A. D., Prati, A., Santagni, S., Ricchieri, F., Chierchia, E., Rattighieri, E., Campedelli, A., Simoncini, T., & Artini, P. G.
- Venue
- Gynecological Endocrinology
- Publisher
- Informa UK Limited
- Published
- 2012-05-21
- Volume
- 28
- Issue
- 12
- Pages
- 969-973
- ISSN
- 0951-3590 (ISSN-L)
- 1473-0766
- OpenAlex
- W2136318705
- Cited by
- 88
- References
- 7
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. https://app.cochat.ai/papers/10.3109/09513590.2012.685205
- The paper
- Genazzani, A. D., Prati, A., Santagni, S., Ricchieri, F., Chierchia, E., Rattighieri, E., Campedelli, A., Simoncini, T., & Artini, P. G. (2012). Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecological Endocrinology. https://doi.org/10.3109/09513590.2012.685205
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.